{"filing":{"accession_number":"0001104659-26-088662","cik":"0001566044","ticker":"VYNE","company_name":"Yarrow Bioscience, Inc.","form":"8-K","filing_date":"2026-07-30","report_date":"2026-07-29","primary_document":"tm2621655d2_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1566044/000110465926088662/tm2621655d2_8k.htm"},"events":[{"id":22563,"run_id":20413,"accession_number":"0001104659-26-088662","anchor_item_number":"8.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"summary":"Yarrow Bioscience entered into an exchange agreement on July 29, 2026, whereby an existing stockholder exchanged 133,290 shares of common stock for pre-funded warrants to purchase 133,290 shares at $0.0001 per share. The transaction results in the issuance of unregistered securities (pre-funded warrants) relying on Section 3(a)(9) exemption, and materially increases dilution: post-exchange, the company will have 2,669,788 shares outstanding but pre-funded warrants to purchase 25,914,530 additional shares. This is a classic dilutive issuance that would materially affect a reasonable investor's assessment of ownership and voting power.","company_name":"Yarrow Bioscience, Inc.","ticker":"VYNE","filing_date":"2026-07-30","form":"8-K","submitted_at":null,"items":[{"id":22540,"accession_number":"0001104659-26-088662","item_number":"8.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"Yarrow Bioscience entered into an exchange agreement on July 29, 2026, whereby an existing stockholder exchanged 133,290 shares of common stock for pre-funded warrants to purchase 133,290 shares at $0.0001 per share. The transaction results in the issuance of unregistered securities (pre-funded warrants) relying on Section 3(a)(9) exemption, and materially increases dilution: post-exchange, the company will have 2,669,788 shares outstanding but pre-funded warrants to purchase 25,914,530 additional shares. This is a classic dilutive issuance that would materially affect a reasonable investor's assessment of ownership and voting power.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-01T02:19:35.958023+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":22540,"accession_number":"0001104659-26-088662","item_number":"8.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"Yarrow Bioscience entered into an exchange agreement on July 29, 2026, whereby an existing stockholder exchanged 133,290 shares of common stock for pre-funded warrants to purchase 133,290 shares at $0.0001 per share. The transaction results in the issuance of unregistered securities (pre-funded warrants) relying on Section 3(a)(9) exemption, and materially increases dilution: post-exchange, the company will have 2,669,788 shares outstanding but pre-funded warrants to purchase 25,914,530 additional shares. This is a classic dilutive issuance that would materially affect a reasonable investor's assessment of ownership and voting power.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-01T02:19:35.958023+00:00","company_name":"Yarrow Bioscience, Inc.","ticker":"VYNE","filing_date":"2026-07-30"}]}